Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Clinical Pathology (Thousand Oaks, Ventura County, Calif.)
|
April 3, 2023
Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease
Nicole Ng, Dean Tai, Yayun Ren, et al.
Journal of Hepatology
|
July 2, 2022
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
Nikolai V Naoumov, Dominique Brees, Juergen Loeffler, et al.
Alimentary Pharmacology & Therapeutics
|
January 17, 2023
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
Mazen Noureddin, Zachary Goodman, Dean Tai, et al.
JHEP Reports : Innovation in Hepatology
|
July 17, 2025
Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy
Daniel T Field, Yayun Ren, Kutbuddin Akbary, et al.
Diagnostics (Basel, Switzerland)
|
August 29, 2024
AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response
Feng Liu, Yameng Sun, Dean Tai, et al.
Journal of Hepatology
|
February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Stephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Journal of Hepatology
|
March 27, 2026
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial
Jörn M Schattenberg, Pierre Bedossa, Cynthia D Guy, et al.
Journal of Hepatology
|
October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam
|
July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial
Tarek Hassanein, Dean Tai, Chenghai Liu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 4, 2024
AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory study
Hai-Yang Yuan, Xiao-Fei Tong, Ya-Yun Ren, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Clinical Pathology (Thousand Oaks, Ventura County, Calif.)
|
April 3, 2023
Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease
Nicole Ng, Dean Tai, Yayun Ren, et al.
Journal of Hepatology
|
July 2, 2022
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
Nikolai V Naoumov, Dominique Brees, Juergen Loeffler, et al.
Alimentary Pharmacology & Therapeutics
|
January 17, 2023
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis
Mazen Noureddin, Zachary Goodman, Dean Tai, et al.
JHEP Reports : Innovation in Hepatology
|
July 17, 2025
Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy
Daniel T Field, Yayun Ren, Kutbuddin Akbary, et al.
Diagnostics (Basel, Switzerland)
|
August 29, 2024
AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response
Feng Liu, Yameng Sun, Dean Tai, et al.
Journal of Hepatology
|
February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH
Stephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Journal of Hepatology
|
March 27, 2026
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial
Jörn M Schattenberg, Pierre Bedossa, Cynthia D Guy, et al.
Journal of Hepatology
|
October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions
Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
Evidence-Based Complementary and Alternative Medicine : Ecam
|
July 25, 2022
Efficacy and Safety of a Botanical Formula Fuzheng Huayu for Hepatic Fibrosis in Patients with CHC: Results of a Phase 2 Clinical Trial
Tarek Hassanein, Dean Tai, Chenghai Liu, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 4, 2024
AI-based digital pathology provides newer insights into lifestyle intervention-induced fibrosis regression in MASLD: An exploratory study
Hai-Yang Yuan, Xiao-Fei Tong, Ya-Yun Ren, et al.
Page
of 3